Immuron Appoints Senior Vice President of Innovation

11 June 2015, Melbourne, Australia: Australian biopharmaceutical company Immuron Limited (ASX: IMC), is pleased to announce the appointment of Dr Dan Ruben Peres as Senior Vice President of Innovation.

In this newly created role, Dr Peres will be responsible for leading and managing Immuron’s Phase II clinical trial program currently underway for non-alcoholic steatohepatitis (NASH) and to support a US National Institute of Health (NIH) funded Phase II clinical trial program for alcoholic steatohepatitis (ASH).

Dr Peres has served in various clinical and medical managerial roles in pharmaceutical and medical device companies such as Exalenz Biosciences, CarboFix Orthopedics Ltd, NMB Medical Applications Ltd, ByPass Makafim Ltd, IOPTima Ltd and NovoNordisk Israel. In addition, Dr. Peres has been responsible for operational, marketing and business-development activities throughout his career in the life sciences industry. Dr. Peres began his career as a physician and medical director in various roles in the Israeli army.

Dr. Peres’ expertise lies with medical strategy, research and development, and the management of clinical studies and other laboratory processes. He has extensive knowledge of the leading International Centres for Liver Disease and established relationships with Key Opinion Leaders, including those currently participating in Immuron’s NASH and ASH trials. Dr. Peres has been a certified physician since 2002 when he graduated from the Sackler School of Medicine at Tel-Aviv University.

Regarding his recent appointment as Immuron’s Senior Vice President of Innovation, Dr Peres said:

“Immuron is an exciting company with a unique technology platform and I am pleased with this opportunity to lead the company’s pipeline forward to achieving its next milestones.”

Dr Peres’ extensive knowledge and experience means he is exceptionally well suited for the role of Senior Vice President of Innovation to lead the Company’s innovative programs, in particular the overall management of the current Phase II NASH and ASH clinical trials.

Immuron Chairman Dr Roger Aston said:

“The Board is pleased to welcome Dan to Immuron as Senior Vice President of Innovation. Immuron is well placed to capitalise on the growing demand for treatment of NASH and as such dedicating a role to the completion of this trial will deliver substantial value to Immuron. Dr Peres will report to the Board and work closely with our CEO Leearne Hinch.”

Contacts:

Dr Roger Aston
Chairman
+61 (0) 402 762 204

Amanda Loh
Buchan Consulting
+61 (0)3 9866 4722
ABOUT IMMURON

Immuron Ltd (ASX:IMC) is a biopharmaceutical company focused on developing and commercialising oral immunotherapies based on its hyperimmune colostrum technology for the treatment of intestinal and liver diseases. The company currently markets Travelan® for the prevention of travellers’ diarrhoea, its lead product candidate IMM-124E is in Phase 2 clinical trials for NASH and ASH, and it has a preclinical immunotherapy pipeline targeting immune-related diseases with unmet needs. Immuron’s main scientific alliances are with Hadassah Medical Center (Israel) and Monash University (Australia).

About IMM-124E and NASH

Non-Alcoholic Steatohepatitis (NASH) refers to a spectrum of conditions of the liver all of which involve chronic inflammation of the liver and is highly correlated with obesity, diabetes and high cholesterol. If left untreated NASH may lead over time to fibrosis and then cirrhosis of the liver and severe liver dysfunction. NASH is increasingly a cause of liver cancer and the need for a liver transplant. Immuron’s Phase II trial for IMM-124E is well positioned to leverage this large and growing market with currently no available drug available on the market.

About IMM-124E and ASH

Alcoholic Steatohepatitis (ASH) refers to inflamed fatty liver disease caused by excessive alcohol consumption. Immuron is funded by the US National Institutes of Health (NIH) for the development of its IMM-124E Phase II trial for ASH. Notably, the NIH has chosen to fund IMM-124E as one of three potential treatments for ASH chosen from 27 potential treatments.